T. Rowe Price Associates
HARP

T. Rowe Price Associates’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

T. Rowe Price Associates’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,823
Closed -$140K – 3024
2022
Q1 		$140K Buy
2,823
+450
+19% +$23.3K ﹤0.01% 2789
2021
Q4 		$179K Buy
2,373
+890
+60% +$60.7K ﹤0.01% 2783
2021
Q3 		$117K Hold
1,483
– – ﹤0.01% 2821
2021
Q2 		$206K Buy
1,483
+75
+5% +$14.3K ﹤0.01% 2721
2021
Q1 		$295K Buy
1,408
+12
+0.9% +$2.4K ﹤0.01% 2572
2020
Q4 		$232K Hold
1,396
– – ﹤0.01% 2518
2020
Q3 		$237K Buy
+1,396
New +$201K ﹤0.01% 2372

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's HARP Position: Q2 2022 in Review

T. Rowe Price Associates sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2022, closing a stake of 2,823 shares — an estimated $140K sold.

T. Rowe Price Associates first reported a position in HARP in Q3 2020 and held it in 7 quarters. The position peaked at $295K in Q1 2021. 63 funds tracked by Wall St. Rank hold HARP as of Q2 2022.

  • T. Rowe Price Associates reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,823 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $140K.
  • T. Rowe Price Associates first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
  • T. Rowe Price Associates's Harpoon Therapeutics, Inc. Common Stock position peaked at $295K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.